Carotuximab: all 25 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate CancRecruitingNCT05534646Phase 2
- Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung CancerRecruitingNCT05401110Phase 1
- Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLCCompletedNCT03780010Phase 1Results posted
- Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration SubjectsCompletedNCT03211234Phase 2Results posted
- Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLCCompletedNCT03181308Phase 1Results posted
- Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced AngiosarcomaCompletedNCT02979899Phase 3Results posted
- Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)TerminatedNCT02664961Phase 2Results posted
- Trial of TRC105 and Sorafenib in Patients With HCCCompletedNCT02560779Phase 1/2Results posted
- Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast CancerCompletedNCT02520063Phase 1/2Results posted
- TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory ChoriocarcinomaCompletedNCT02396511Phase 2Results posted
- A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue SarcomaCompletedNCT01975519Phase 1/2Results posted
- Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell CarcinomaTerminatedNCT01806064Phase 1/2Results posted
- TRC105 for Recurrent GlioblastomaTerminatedNCT01778530Phase 2Results posted
- Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney CancerCompletedNCT01727089Phase 2Results posted
- Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT01648348Phase 1/2Results posted
- A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With GlioblastomaCompletedNCT01564914Phase 2Results posted
- Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaCompletedNCT01381861Phase 2Results posted
- TRC105 for Liver Cancer That Has Not Responded to SorafenibCompletedNCT01375569Phase 2Results posted
- Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is IndicatedCompletedNCT01332721Phase 1Results posted
- TRC105 in Adults With Advanced/Metastatic Urothelial CarcinomaCompletedNCT01328574Phase 2Results posted
- Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast CancerCompletedNCT01326481Phase 1/2Results posted
- Sorafenib and TRC105 in Hepatocellular CancerCompletedNCT01306058Phase 1/2Results posted
- A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)CompletedNCT01090765Phase 1/2Results posted
- A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung CancerCompletedNCT02429843Phase 1
- Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid CancerCompletedNCT00582985Phase 1